Marie-helene H. Larue-Delfau

Université Paris Est
Creteil, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Large B-cell lymphoma: The LYSA pragmatic guidelines.

Large B-cell lymphoma: The LYSA pragmatic guidelines.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 21, 2025

Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.

Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.

Journal: Blood advances

Published: January 02, 2025

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.

Journal: Blood

Published: November 18, 2024

Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.

Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.

Journal: Leukemia

Published: October 31, 2024

Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study.

Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study.

Journal: Blood cancer journal

Published: October 04, 2024

Induction of p53-mediated apoptosis by azacitidine in patient-derived xenograft follicular helper T-cell lymphoma model.

Induction of p53-mediated apoptosis by azacitidine in patient-derived xenograft follicular helper T-cell lymphoma model.

Journal: Leukemia

Published: September 19, 2024

Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.

Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 16, 2024

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.

Journal: The Lancet. Haematology

Published: January 23, 2024

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.

Journal: Blood

Published: January 12, 2024

Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.

Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 22, 2023

Angioimmunoblastic T-cell lymphoma and Kaposi sarcoma: A fortuitous collision?

Angioimmunoblastic T-cell lymphoma and Kaposi sarcoma: A fortuitous collision?

Journal: Histopathology

Published: August 26, 2023

Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort.

Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort.

Journal: British journal of haematology

Published: January 16, 2023

Showing 1-12 of 57

Last Updated: 09/26/2026